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Recent admixture mapping and linkage/association studies have
implicated an 1 Mb region on chromosome 8q24 in prostate can-
cer susceptibility. In a subsequent follow-up investigation, Haiman
et al. (Nat Genet 2007;39:638-44) observed significant, independ-
ent associations between 7 markers within this region and spo-
radic prostate cancer risk in a multi-ethnic sample. To clarify the
risk associated with hereditary prostate cancer, we tested for pros-
tate cancer association with 6 of these 7 markers in a sample of
1,015 non-Hispanic white men with and without prostate cancer
from 403 familial and early-onset prostate cancer families. Single
nucleotide polymorphisms (SNPs) rs6983561 and rs6983267
showed the strongest evidence of prostate cancer association.
Using a family-based association test, the minor (‘‘C’’) allele of
rs6983561 and the major (‘‘G’’) allele of rs6983267 were preferen-
tially transmitted to affected men (p < 0.05), with estimated odds
ratios (ORs) of 2.26 (95% confidence interval of 1.06–4.83) and
1.30 (95% confidence interval of 0.99–1.71), respectively, for an
additive model. Notably, rs6983561 was significantly associated
with prostate cancer among men diagnosed at an early (<50 years)
but not later age (p 5 0.03 versus p 5 0.21). Similarly, the associa-
tion with rs6983267 was (not) statistically significant among men
with(out) clinically aggressive disease (p 5 0.007 versus p 5 0.34).
Our results confirm the association of prostate cancer with several
of the SNPs on chromosome 8q24 initially reported by Haiman
et al. In addition, our results suggest that the increased risk associ-
ated with these SNPs is approximately doubled in individuals pre-
disposed to develop early onset or clinically aggressive disease.
' 2008 Wiley-Liss, Inc.
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Prostate cancer is now the most commonly diagnosed malig-
nancy among men in the United States, with over 218,890 new
cases and 27,050 deaths expected in 2007 according to the
National Cancer Institute. Although the majority of prostate can-
cer cases are sporadic, twin and family-based epidemiological
studies consistently provide clear evidence of a substantial herit-
able component of the disease.1 However, given the late-onset
nature, lack of distinguishing clinical features between sporadic,
familial and hereditary forms, and likely genetic heterogeneity of
the disease, the localization and validation of prostate cancer sus-
ceptibility genes has been difficult. In this context, recent studies
of chromosome 8 have provided promising leads and new insights
into the genetics underlying prostate cancer susceptibility.
Amundadottir et al.2 recently identified a region on chromo-
some 8, namely 8q24, which was linked to prostate cancer in their
Icelandic families. Further fine mapping of this region led to the
identification of several markers that were associated with prostate
cancer in men with European and African American ancestry. At
the same time, Freedman et al.3 independently implicated the
8q24 region in prostate cancer susceptibility in a whole genome
admixture scan of African American men. In addition to the
admixture scan, they (Haiman et al.)4 later conducted a high-den-
sity association scan of the 8q24 region and reported 7 markers
(within a span of 500 kb) that were significantly and independ-
ently associated with prostate cancer in a multi-ethnic sample of
African, European and Japanese Americans, Native Hawaiians
and Latinos.
While the markers identified by Haiman et al.4 have been well
characterized in samples of men with sporadic prostate cancer,
their influence on prostate cancer among men with a strong herit-
able component to their disease has not been specifically studied.
For example, in the sample of Haiman et al.4, only 16% of men
with prostate cancer reported a family history of the disease, and
50% were more than 68 years old at diagnosis. To address the
impact of variation on chromosome 8q24 in the context of heredi-
tary prostate cancer, we examined prostate cancer association with
the significantly associated markers from Haiman et al.4 in our




The University of Michigan Prostate Cancer Genetics Project
(PCGP) has been described in detail elsewhere.5 Briefly, enroll-
ment into the PCGP is restricted to (i) men diagnosed with pros-
tate cancer with at least one living first- or second-degree relative
also diagnosed with prostate cancer or (ii) men diagnosed with
prostate cancer at 55 years of age without a family history of the
disease. For the present analysis, 421 families were identified in
which DNA was available from at least one pair of brothers dis-
cordant for prostate cancer. The majority of these 421 families
were non-Hispanic white (n 5 403), although 16 African Ameri-
can and 2 Asian families were also recruited. Results below, how-
ever, were restricted to non-Hispanic white families as the number
of African American and Asian families was too small to make
meaningful inferences about prostate cancer risk in these minority
groups.
The majority of PCGP families were recruited directly from the
University of Michigan Comprehensive Cancer Center. Diagnosis
of prostate cancer was confirmed by review of pathology reports
or medical records, and age at diagnosis was calculated from the
date of the first positive biopsy for prostate cancer. Cases were
classified as clinically aggressive if they met at least one of the
following criteria: (i) pathologic Gleason score > 7, or (ii) patho-
logic stage T3b (pT3b) tumor (indicating seminal vesicle involve-
ment) and higher, or (iii) N1 (positive nodal involvement), or (iv)
pathologic Gleason score of 7 and a positive surgical margin, or
(v) a pre-diagnostic serum prostate-specific antigen (PSA) value
>15 ng/ml, or (vi) or a pre-diagnostic serum PSA level > 10 ng/
ml and a Gleason score of 7. On the basis of data from D’Amico
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et al.6 these criteria were developed by the Southwest Oncology
Group (SWOG) to identify men at intermediate to high risk of
clinical recurrence after primary therapy. Disease status of the
unaffected brothers was confirmed through serum PSA testing
whenever possible. The Institutional Review Board at the Univer-
sity of Michigan Medical School approved all aspects of the proto-
col, and all participants gave written informed consent, including
permission to release their medical records.
Genotyping assays
We genotyped five SNPs (rs13254738, rs6983561, rs6983267,
rs7000448 and rs10090154) using Taqman SNP Genotyping
Assays (Applied Biosystems, Foster City, CA), and we used the
ABI PRISM 7900HT Sequence Detection System and the SDS
version 2.1 software (Applied Biosystems) to distinguish SNP
alleles as previously described.5 Note, we did not genotype the
sixth prostate cancer-associated SNP identified by Haiman et al.4
(Broad11934905) due to the low frequency of the minor allele in
non-African populations (<1%). We genotyped microsatellite
DG8S737 using a fluorescently labeled PCR followed by capillary
electrophoresis. We electrophoresed PCR products on an ABI
3100 Genetic Analyzer and analyzed the resulting data using Gen-
eMapper Software v4.0 (Applied Biosystems) as previously
described.7 For each SNP, 9% of samples were duplicated on
the same platform, and 2% of samples were directly sequenced
for verification purposes. For the microsatellite, 5% of samples
were repeated for verification purposes. No genotype discrepan-
cies were observed.
Data analysis
On the basis of a subset of unaffected, unrelated men, we tested
the observed genotype distributions for departures from Hardy-
Weinberg equilibrium and estimated two-marker haplotype fre-
quencies using the expectation-maximization algorithm. Haplo-
type frequencies were used to calculate the LD measure r2
between each pair of markers. For association testing, we used
conditional logistic regression with family as the stratification
variable and a robust variance estimate that incorporates familial
correlations due to potential linkage to estimate odds ratios (ORs)
and 95% confidence intervals (CIs) for the association between ge-
notypes and prostate cancer.8 In parallel, we used the Family-
Based Association Test (FBAT) program (version 1.7.3)9,10 to test
for association between genotypes and prostate cancer. We
employed the empirical variance function in FBAT, which is a
valid test of the null hypothesis of no association in the presence
of linkage. To maximize power, we analyzed the combined sam-
ple of affected and unaffected men using the offset option. We
also carried out analyses of affected men only to allow for the pos-
sibility of misclassification of unaffected men. Both conditional
logistic regression analyses and FBATs were carried out assuming
additive, dominant and recessive genetic models. For conditional
logistic regression and affecteds-only FBATs, we also examined a
general (2 degrees of freedom) genotype model. Predetermined
stratified analyses were also performed to explore the relationship
between genotypes and prostate cancer, stratifying on the presence
of clinically aggressive prostate cancer, age at diagnosis (<50
years), and number of confirmed cases of prostate cancer within a
family (3). All statistical tests were two-sided, and p-values
<0.05 were considered statistically significant. Conditional logis-
tic regression was conducted using version 8.2 of the SAS pro-
gramming language (SAS Institute, Cary, NC). All remaining
analyses (except where noted above) were conducted using the R
language (version 2.1.1).
Results
For this analysis, we identified 542 affected and 473 unaffected
men from 403 non-Hispanic white families with at least 1 discord-
ant sibling pair (DSP). In total, the sample consisted of 624 DSPs
from 421 sibships. The clinical characteristics of men with pros-
tate cancer are summarized in Table I. The median age at diagno-
sis was 54 years, and 116 cases (21%) were diagnosed before 50
years of age. On the basis of SWOG criteria, 30% of prostate
cancer cases were classified as having clinically aggressive dis-
ease. Over 90% of unaffected men reported having been screened
for prostate cancer. In addition, 80% of unaffected men reported
their most recent PSA test results and/or had their PSA values con-
firmed by medical record review, and nearly 95% of them had
documented PSA levels < 4.0 ng/ml.
Allele frequencies for all 6 markers are given in Table II. There
were no significant differences in the distribution of alleles or ge-
notypes between affected and unaffected men when ignoring fam-
ily structure and treating all men as unrelated subjects (data not
shown). On the basis of a sample of unrelated, unaffected men, the
genotype distributions of all markers were consistent with Hardy-
Weinberg equilibrium (p-value > 0.05), and all 10 SNP pairs
exhibited weak LD (r2  0.2). After collapsing the alleles of
DG8S737 (28 versus all others), DG8S737 also exhibited weak
LD with the SNPs (maximum r2 of 0.32 with rs10090154).
Tables II and III summarize association results (under an addi-
tive model) for all 6 markers from FBATs and conditional logistic
regression analyses, respectively. For the FBAT results that fol-
low, we report findings from the combined sample of affected and
unaffected men, unless otherwise specified. Before conducting the
conditional logistic regression analysis, we excluded 38 men
(from 10 families) who were not brothers of the index case; the
resulting sample consisted of 977 men and 604 DSPs. The strong-
est evidence of prostate cancer association was for SNPs
rs6983561 and rs6983267. The minor allele (‘‘C’’) of rs6983561
was preferentially transmitted to affected men (z 5 2.21; p 5
0.03), with an odds ratio of 2.26 (95%CI 5 1.06, 4.83). In con-
trast, the major allele (‘‘G’’) of rs6983267 was preferentially trans-
mitted to affected men (z 5 2.07; p 5 0.04), with an odds ratio of
1.30 (95%CI 5 0.99, 1.71). Under a dominant (but not additive)
genetic model, rs7000448 revealed suggestive but nonsignificant
evidence of prostate cancer association (z 5 1.87; p 5 0.06), with
an odds ratio of 1.44 (95%CI 5 0.97, 2.11) for carriers of the
minor or ‘‘T’’ allele. None of the remaining markers (rs13254738,
rs10090154 or DG8S737) were associated with prostate cancer
risk.
After stratification, the minor allele (‘‘C’’) of rs6983561 was
preferentially transmitted to men diagnosed with prostate cancer
before the age of 50 years relative to their unaffected brothers (z
5 2.19; p 5 0.03 for an additive model), with an odds ratio of
4.69 (95% CI 5 0.86, 25.6). Similarly, the major allele of
rs6983267 (‘‘G’’) was preferentially transmitted to men diagnosed
with clinically aggressive disease (z 5 2.69; p 5 0.007 for an
additive model), with an odds ratio of 1.90 (95% CI 5 1.09, 3.31).
These stratified results are consistent with the FBAT results based
TABLE I – CHARACTERISTICS OF MEN WITH PROSTATE
CANCER (n 5 542)
Characteristic No.1 (%)
Age at diagnosis (years)2 54 (50–62)










Clinically aggressive CaP (%) 162 (30)
1Column subtotals do not sum to 542 due to missing data.–2Median
and [interquartile range] are reported.–3Number and (percentage) of
men with prostate cancer who underwent a radical prostatectomy.
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on all families. In contrast, rs6983561 and rs6983267 were not sig-
nificantly associated with prostate cancer in men diagnosed at a
later age (p 5 0.21) or with nonaggressive disease (p 5 0.34),
respectively. We found no significant evidence of an association
between rs13254738, rs10090154 or DG8S737 and prostate can-
cer in any of the stratified analyses.
Discussion
In summary, we have confirmed that 2 of the 7 prostate cancer-
associated markers on chromosome 8q24 identified by Haiman
et al.4 in their multi-ethnic sample of sporadic prostate cancer are
associated with early-onset and familial prostate cancer in our
sample of non-Hispanic white men. Our 2 significantly associated
markers, SNPs rs6983561 and rs6983267, had the strongest evi-
dence of association in the subset of families in which men were
diagnosed with prostate cancer at an early age or with clinically
aggressive disease, respectively. To our knowledge, we are the
first group to validate the association of prostate cancer with SNP
rs6983561 and the first to report a significant association between
clinically aggressive prostate cancer and SNP rs6983267. Notably,
we estimate that men with one risk allele at SNP rs6983561 are
nearly 5 times more likely to develop early-onset prostate cancer
than men with no risk alleles. Similarly, men with 2 risk alleles at
SNP rs6983267 are nearly 4 times more likely to develop clini-
cally aggressive prostate cancer than men with no risk alleles.
Although our results were not all statistically significant, none
were significantly different from the study of Haiman et al.4 (see
Table III). In fact, based on their European American sample, 5 of
the 6 markers tested by Haiman et al.,4 including rs6983561 and
rs6983267, were nonsignificantly associated with prostate cancer,
possibly reflecting the effects of clinical and genetic heterogeneity
in a smaller sample. Notably, in their pooled, multi-ethnic sample,
the effect of rs6983561 was significantly greater among men diag-
nosed with prostate cancer below the median age of 68 years, con-
sistent with both our overall and stratified results for rs6983561.
Further, indirect support for this association was also recently
given by Gudmundsson et al.,11 who reported early-onset prostate
cancer association with SNP rs16901979, which is perfectly corre-
lated with rs6983561 in the HapMap CEU sample (r2 51).
Finally, like us, Yeager et al.12 also reported a stronger association
between clinically aggressive prostate cancer and SNP rs6983267,
although their result was not statistically significant, perhaps again
owing (in part) to the adverse effects of clinical and genetic
heterogeneity.
Several other groups have also identified markers on chromo-
some 8q24 as being associated with prostate cancer. For example,
multiple studies have reported prostate cancer association with
SNP rs1447295.2,3,11–17 Because of the perfect correlation
between rs1447295 and one of our tested SNPs, rs10090154, in
the HapMap CEU sample (r2 5 1), we did not initially genotype
rs1447295. However, in subsequent genotyping, we found no
association between this SNP and prostate cancer (data not
shown), consistent with our original result for rs10090154. Lastly,
several studies have also reported prostate cancer association with
the –8 allele of microsatellite DG8S737,2,4,15,16 including one
study that reported a stronger association between the –10 allele
and clinically aggressive prostate cancer.16 Still, we found no
association between DG8S737 and clinically aggressive and/or
nonaggressive prostate cancer.
We acknowledge several study limitations. First, our modestly
powered sample limited our ability to detect prostate cancer-
marker associations with the small effect sizes (e.g., odds ratios
less than 1.5) previously reported by Haiman et al.4 and confirmed
by others. For example, based on our current sample of 400 DSP
families and a significance level of 5%, we had a maximum of 26–
64% power to detect prostate cancer association with a single SNP
for odds ratios of 1.2–1.4 and risk allele frequencies from 5 to
95% (under an additive genetic model). Second, because our sam-
ple largely included non-Hispanic white men with early onset and/
or familial prostate cancer, we were unable to generalize our find-
ings, e.g., the association between clinically aggressive prostate
cancer and SNP rs6983267, to other populations. Third, the possi-
bility of preclinical disease among the unaffected men in our study
may have undermined our ability to detect genetic differences
TABLE III – ODDS RATIOS (ORS) (AND 95% CONFIDENCE INTERVALS) IN CURRENT
STUDY1 AND FROM HAIMAN ET AL.4
Non-Hispanic whites2 European Americans1 Multi-ethnic sample1
rs13254738 0.97 (0.74, 1.27) 1.11 (0.97, 1.26) 1.26 (1.18, 1.36)
rs6983561 2.26 (1.06, 4.83) 1.16 (0.86, 1.58) 1.51 (1.37, 1.67)
rs6983267 1.30 (0.99, 1.71) 1.13 (0.99, 1.28) 1.18 (1.09, 1.27)
rs7000448 1.11 (0.85, 1.44) 1.14 (0.93, 1.40) 1.26 (1.15, 1.38)
DG8S737 1.24 (0.74, 2.07) 1.45 (0.96, 2.19) 1.39 (1.23, 1.57)
rs10090154 1.05 (0.72, 1.53) 1.44 (1.17, 1.76) 1.43 (1.30, 1.58)
Note – as in Table II, ORs are based on an additive model for the minor allele, except for rs6983267
(major allele).
1Based on unconditional logistic regression of (1) 2,124 European American men and (2) after adjust-
ment for population and study, 7,518 men from a multi-ethnic sample, including African, European, and
Japanese Americans, Native Hawaiians, and Latinos.–2Based on conditional logistic regression of 977
non-Hispanic white men (604 DSPs in total).










rs13254738 2 A>C 0.34 0.35 191 -0.29 0.78
rs6983561 2 A>C 0.08 0.06 49 2.21 0.03
rs6983267 3 G>T 0.41 0.43 189 2.07 0.04
rs7000448 3 C>T 0.41 0.40 187 0.72 0.47
DG8S737 1 284 0.08 0.07 62 0.71 0.48
rs10090154 1 C>T 0.13 0.13 106 0.06 0.95
1Defined by Haiman et al.4–2Under an additive model for the minor allele, except for rs6983267 (major allele).–3Number of informative fami-
lies.–4Minor allele after collapsing alleles of DG8S737, i.e., 28 versus all others.
http://www.hapmap.org
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between men with and without prostate cancer. Still, when we re-
stricted analyses to the sample of affected men only, our findings
were consistent with those based on analyses of the combined
sample of affected and unaffected men, suggesting that the impact
of any misclassification of unaffected men was likely minimal.
In conclusion, results from a number of studies indicate that
genetic variation on chromosome 8q24 is associated with prostate
cancer, primarily sporadic prostate cancer. Data from our family-
based study, however, suggest that these associations also extend
to early-onset and familial prostate cancer. Furthermore, results
from our stratified analyses indicate that the genetic risk conferred
by these SNPs may be substantially increased, e.g., 2-fold
higher, in men predisposed to develop early-onset or clinically
aggressive prostate cancer. These findings hint at the potential for
early genetic screening to identify a subset of men who are at
greater risk of developing prostate cancer, even in the absence of a
family history of the disease.
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